Sarcomatrix Therapeutics Corp.
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Regenerative Medicine
Sarcomatrix is a clinical-stage biopharmaceutical company dedicated to redefining the treatment of muscle-wasting diseases through the power of regenerative medicine. Our mission is to develop first-in-class therapeutics that not only delay disease progression but actively promote muscle repair and fiber stabilization in patients with Muscular Dystrophy (genetic defect leading to muscle loss), sarcopenia (primarly age related muscle loss), and cachexia (muscle loss secondary to chronic disease, chemo therapy, or GLP-1 therapy).
Company HQ City:
Reno
Company HQ State:
NV
Company HQ Country:
United States
Year Founded:
2022
CEO
David Craig, CEO
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}